Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-496.39	-465.32	-298.41	-214.53	-163.92	-107.64
Depreciation & Amortization	4.13	3.89	2.79	1.1	0.98	0.92
Stock-Based Compensation	100.23	91.02	69.39	40.94	28.27	17.35
Other Adjustments	-10.31	-12.36	-11.37	-1.86	0.85	-0.32
Change in Receivables	-5.09	-0.59	-	-	-	-
Changes in Inventories	-0.91	-2.02	-	-	-	-
Changes in Accounts Payable	0.45	28.98	13.32	12.36	10.99	6.29
Changes in Unearned Revenue	-1.9	-1.84	0.07	-1.54	8.34	-
Changes in Other Operating Activities	-19.58	-19.69	-5.98	-5.07	-0.72	-5.2
Operating Cash Flow	-414.17	-377.92	-230.19	-168.6	-115.21	-88.59
Capital Expenditures	-5.34	-5.76	-3.84	-4.69	-1.66	-0.44
Purchases of Investments	-1,168	-1,004	-1,147	-532.86	-329.82	-125.4
Proceeds from Sale of Investments	1,181	1,184	575.8	337.13	157.49	69.36
Investing Cash Flow	7.51	173.91	-574.82	-200.41	-173.98	-56.48
Issuance of Common Stock	425.32	40.61	1,030	391.78	121.96	252.68
Net Common Stock Issued (Repurchased)	425.32	40.61	1,030	391.78	121.96	252.68
Other Financing Activities	-0.58	-	-14.98	-0.54	-	-
Financing Cash Flow	426.05	40.61	1,015	391.24	121.96	252.68
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.01	-0.11	-	-	-	-
Net Cash Flow	19.39	-163.4	209.65	22.22	-167.22	107.61
Free Cash Flow	-419.52	-383.68	-234.04	-173.29	-116.86	-89.02
FCF Margin	-2321.74%	-4985.50%	-22525.30%	-4318.12%	-2466.98%	-8258.26%
Free Cash Flow Per Share	-4.33	-4.08	-2.90	-2.98	-2.25	-2.32
Levered Free Cash Flow	-519.55	-461.76	-292.06	-212.37	-145.98	-106.06
Unlevered Free Cash Flow	-569.17	-513.41	-332.5	-220.45	-149.94	-106.12

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q